Fresenius Medical Care offers a comprehensive range of acute haemodialysis options specifically designed to allow immediate access to reliable technology in life-threatening situations. These include a comprehensive product portfolio for successful continuous renal replacement and hybrid therapy modalities.
Fresenius Medical Care introduced a hybrid form of acute renal replacement therapy, known as prolonged intermittent renal replacement therapy (PIRRT). PIRRT is designed to provide highly efficient on-line haemodiafiltration on a daily basis thereby offering an alternative, cost-efficient convective treatment for critically ill patients with acute renal failure.
The 5008 therapy system
As the world's largest integrated provider of dialysis products and services, Fresenius Medical Care has set new safety standards with the 5008 therapy system, a closed circuit, volumetric fluid balancing system with intelligent safety measures.
5008 therapy system key features include:
Extended daily diafiltration (EDD-f)
EDD-f is a hybrid therapy that delivers a gentle yet effective diffusive and convective treatment for patients with acute renal failure. Combining the advantages of conventional dialysis and continuous renal replacement therapy, EDD-f further enhances renal replacement techniques in treating acute renal failure over an extended 6 – 10 hour period.
As part of our commitment to advancing acute dialysis therapies, Fresenius Medical Care continues to develop innovative treatment tools and promising new techniques that serve medical needs today and into the future. Key priorities include: